Earnings - 13th Nov 2008

4:05PM Freeseas beats by $0.04, reports revs in-line (FREE) 1.68 -0.30 : Reports Q3 (Sep) earnings of $0.44 per share, $0.04 better than the two analyst est of $0.40; revenues rose 357.4% year/year to $22.3 mln vs the $22.2 mln two analyst est. The co also reported a 191% increase in operating days in the third quarter of 2008 compared with same period in 2007.

4:01PM Kohl's beats by $0.01; lowers Q4 EPS guidance below consensus (KSS) 30.45 +1.58 : Reports Q3 (Oct) earnings of $0.52 per share, $0.01 better than the First Call consensus of $0.51; revenues fell 0.6% year/year to $3.8 bln vs the $3.87 bln consensus. Co issues downside guidance for Q4, sees EPS of $0.90-1.05 vs. $1.22 consensus, prior guidance $1.26-1.34

8:35AM Pan Am Silver misses by $0.02, misses on revs (PAAS) 9.77 : Reports Q3 (Sep) earnings of $0.14 per share, excluding non-recurring items, $0.02 worse than the First Call consensus of $0.16; revenues fell 9.6% year/year to $79.5 mln vs the $92 mln consensus. During the quarter the co generated $22.7 mln in cash flow from operating activities, while investing $33.6 mln in construction of the new Manantial Espejo mine and $14.2 mln in the expansion of the San Vicente mine. Co incurs cap exp. of $11.8 mln at its other operations.

7:01AM ZOLL Medical reports EPS in-line, revs in-line (ZOLL) 19.94 : Reports Q4 (Sep) earnings of $0.41 per share, in-line with the First Call consensus of $0.41; revenues rose 13.8% year/year to $105.6 mln vs the $106.2 mln consensus. "Our backlog did not grow in Q4 as it typically does, and we continue to plan for an environment where capital spending may be constrained. Additionally, the rapid strengthening of the US dollar has created a significant headwind against the reported revenue and earnings of our International operations."

6:20AM Wal-Mart beats by $0.01, reports revs in-line; guides Q4 EPS below consensus; lowers FY09 EPS below consensus (WMT) 52.62 : Reports Q3 (Oct) earnings of $0.77 per share, $0.01 better than the First Call consensus of $0.76; revenues rose 7.5% year/year to $97.63 bln vs the $98.26 bln consensus. Co issues downside guidance for Q4, sees EPS of $1.03-1.07 vs. $1.11 consensus. Co issues downside guidance for FY09, sees EPS of $3.42-3.46 vs. $3.49 consensus, prior guidance $3.43-3.50. For Q409, co estimates comp store sales increase to be between 1-3%. "The rapid changes in currency exchange rates during the last few weeks are projected to negatively affect this year's fourth-quarter results by approx $0.06 per share. In U.S. dollar terms, strong operating performance in International may be overshadowed by these currency fluctuations," commented CFO Tom Schoewe.

6:12AM Fortress Investment misses by $0.14, beats on revs (FIG) 3.24 : Reports Q3 (Sep) loss of $0.04 per share, $0.14 worse than the First Call consensus of $0.10; revenues fell 25.1% year/year to $185.1 mln vs the $164.7 mln consensus.

6:05AM Urban Outfitters reports EPS in-line, revs in-line (URBN) 15.21 : Reports Q3 (Oct) earnings of $0.35 per share, in-line with the First Call consensus of $0.35; revenues rose 26.0% year/year to $478 mln vs the $478.9 mln consensus.

1:51AM Global Sources reports EPS in-line, misses on revs; guides Q4 EPS below consensus, revs below consensus (GSOL) 5.93 : Reports Q3 (Sep) earnings of $0.04 per share, excluding non-recurring items, in-line with the First Call consensus of $0.04; revenues rose 11.2% year/year to $37.6 mln vs the $38.8 mln consensus. Co issues downside guidance for Q4, sees EPS of $0.14-0.15, excluding non-recurring items, vs. $0.24 consensus; sees Q4 revs of $63.0-64.0 mln vs. $70.20 mln consensus. 2H08 revenue is expected to be $101.0-101.5 mln; 2H08 non-GAAP EPS is expected to be $0.18-0.19, excluding items.

12:06AM WuXi PharmaTech beats by $0.01, misses on revenue (WX) 7.84 : Reports Q3 (Sep) earnings of $0.10 per share, $0.01 better than the First Call consensus of $0.09; revenues increased 98% year/year to $67.5 mln vs the $68.35 mln consensus. Co reaffirms guidance; sees FY08 revenue of $260.0-265.0 mln vs the $265.58 mln consensus. Adjusted Ebitda is expected to be $70.0-75.0 mln, excluding items.